Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI-524 prophylaxis study in children with hemodynamically significant congenital heart disease
2005-001671-35Phase 2Completed
- Sponsor
- MedImmune
- Start
- Jun 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of motavizumab in respiratory syncytial virus disease (RSV) (2 arms), sponsored by MedImmune. Primary endpoint: Safety and tolerability through Study Day 150. Started Jun 2005; status: completed.
02
Drugs
motavizumab
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2005-001671-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001671-35.